ClinicalTrials.gg
CompletedNCT04588129Updated May 4, 2022

Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers

A Phase 1 interventional study of LB-102 in Schizophrenia, sponsored by LB Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-04.

Sponsored by LB Pharmaceuticals Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,465 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Enrollment
1,153rd of 1,319
16 · median 66
Started
2021
with 52 others
Phase 1
196 of 1,465
10 open now
Registered
1,194th of 1,465
by date

Among the 1,465 studies in Schizophrenia with a site in United States, this one is the 1,153rd largest by enrollment of the 1,319 interventional ones that give a count, is one of 53 that started in 2021, is one of 196 in phase 1, and was the 1,194th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,465 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,465 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

This is an open label study in 4 cohort of 4 healthy volunteers each designed to evaluate the dopamine receptor occupancy of LB-102 at various doses and timepoints.

Read the detailed description

This is a Phase 1, open label study designed to evaluate the dopamine receptor occupancy in healthy subjects. There will be 4 cohorts consisting of 4 subjects each. Eligible subjects will receive 1 or 2 doses of LB-102 on Day 1: subjects in the final cohort will be dosed for 5 days BID (ie twice/day) on an inpatient basis. This will be an open label study. Blood samples for pharmacokinetic (PK) and safety assessments will be collected at screening, immediately pre-dose, and during/before/after PET scan. Subjects enrolled in the inpatient cohort will be monitored daily. Follow-up after discharge will consist of a phone call the evening of discharge and the next day to check on subjects. This will be an adaptive study and doses in cohorts 2-4 will be determined after PET data from Cohort 1 are obtained.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(BMI) ≥ 18 and ≤ 30 kg/m2 at screening visit. Competent to provide .

Subjects must be in good general health as determined by medical history and physical examination with no medical findings and no history of significant medical disease (e.g., cardiovascular, pulmonary, renal, etc.) or acute condition with the past 30 days, as determined by the study investigators.

Have normal clinical laboratory test results and , which are not considered to be clinically significant by the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Are pregnant or lactating.
  2. Have a history or presence of significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological or psychological/psychiatric disorders which, in the opinion of the Investigator, increases the risk of the study drug or may confound the interpretation of study measures.
  3. abnormal findings on physical examination or vital signs as determined by Investigator.
  4. Individuals with pacemakers, aneurysm clips, shrapnel, or other restricted implanted metallic devices will be excluded from study. All subjects complete the standard MRI screening questionnaire prior to MRI.
  5. History or presence of psychiatric or neurological disease or condition, as determined by the Investigator.
  6. History of seizures.
  7. Subject with any history or current evidence of suicidal behavior.
  8. Unwilling to complete any planned study assessments.
  9. Have a history of blood donation in excess of 500 mL of blood within 30 days prior to Screening.
  10. Have received treatment with an drug or device within 30 days prior to Screening.
  11. Have a positive test for (HIV) antibodies 1 and 2, Surface Antigen (HBsAg) or Virus (HCV) antibody.
  12. Any subject who is known to be allergic to the study drug or any components of the study drug.
  13. The subject has a fasting blood glucose ≥ 126 mg/dL or (HbA1c) ≥ 6.5% at Screening.
  14. The subject has a history of or dysrhythmia or a family history of prolonged QT interval or sudden death.
  15. Clinically significant abnormal finding on (electrocardiogram) and/or evidence of any of the following cardiac conduction abnormalities at Screening:

    1. Heart rate \< 40 bpm and > 100 bpm (based on the ECG reading)
    2. QTcF interval > 450 msec for males and females
    3. PR interval ≥ 200 msec
    4. Intraventricular conduction delay with QRS duration > 120 msec
    5. Evidence of second- or third-degree atrioventricular block (AVB)
    6. Electrocardiographic evidence of complete left bundle branch block (LBBB), complete right bundle branch block (RBBB), or incomplete LBBB
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    LB-102 50 mg, single dose Cohort 1

    LB-102 (N-Methyl amisulpride) formulated capsule will be administered orally once daily for one day in 4 subjects.

    Drug: LB-102

  • Experimental
    LB-102 100 mg, single dose Cohort 2

    LB-102 (N-Methyl amisulpride) formulated capsule will be administered orally once daily for one day in 4 subjects.

    Drug: LB-102

  • Experimental
    LB-102 75 mg, single dose Cohort 3

    LB-102 (N-Methyl amisulpride) formulated capsule will be administered orally once daily for one day in 4 subjects.

    Drug: LB-102

  • Experimental
    LB-102 100 & 50 mg, multiple dose Cohort 4

    LB-102 (N-Methyl amisulpride) formulated capsule will be administered orally once daily for four days in 4 subjects: 2 subjects @ 100 mg and 2 subjects @ 50 mg.

    Drug: LB-102

Interventions

  • DrugLB-102

    (N-Methyl amisulpride)

06

What researchers measure

Primary outcomes

  1. Brain Receptor Occupancy as Measured by Positron Emission Tomography

    PET scan of D2/D3 receptor occupancy using raclopride as a tracer

    Time frame: 2.5 hours post LB-102 dose

  2. Brain Receptor Occupancy as Measured by Positron Emission Tomography

    PET scan of D2/D3 receptor occupancy using raclopride as a tracer

    Time frame: 7.5 hours post LB-102 dose

  3. Brain Receptor Occupancy as Measured by Positron Emission Tomography

    PET scan of D2/D3 receptor occupancy using raclopride as a tracer

    Time frame: 23.5 hours post LB-102 dose

Secondary outcomes

  1. Safety and Tolerability as Measured by Reported Adverse Events

    Measurement of clinical events as determined by medical staff reporting

    Time frame: Up to 14 days

07

Study locations

1 site
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Sep 2021, 8 months.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 8 months is below that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2020
First posted
Oct 19, 2020
StartActual
Jan 5, 2021
Primary completionActual
Sep 17, 2021
CompletionActual
Nov 15, 2021
Last update
May 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04588129
Lead sponsor
LB Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Oct 19, 2020
Start date
Jan 5, 2021
Primary completion
Sep 17, 2021
Completion
Nov 15, 2021
Last update
May 4, 2022

Study contacts

Dean Wong, PhD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LB-102

Start the discussion